PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Mepartricin (Ipertrofan) in the treatment of BPH patients
Article published in Urologia Polska 1992/45/4.

authors

Andrzej Prajsner, Adam Szkodny, Wiesław Duda, Andrzej Szurkowski, Michał Tkocz
I Katedra i Klinika Urologii Śląskiej AM w Katowicach Kierownik: prof. dr hab. n. med. A. Szkodny

summary

Subject of study was a group of 20 males with the lst grade of BPH, aged 48-77 (mean age 64.3), who received ipertrofan (Mepartricin SPA, Italy) administered 3 times daily — 50.000 for 30 days. After 30 days of drug administration significant moderation of pollakisuria was found, both daily and nocturnal, increase of functional capacity of the bladder and decrease in urine retention. No statistically significant changes of the adenoma size were observed, but there was a significant improvement of the urethral flow.
Very good tolerance of the drug was confirmed. Diminishing of symptoms and improvement of miction parameters by at least 1/3 of their initial values was achieved in 75,0% of the treated patients. It seems well grounded to continue administration of the drug in these patients.

references

  1. 1. Boyarsky S., Jones G., Paulson D. F.\\\\ A new look at bladder neck obstruction by the food and drug administration regulators: guidelines for investigators of benign prostatic hypertrophy. Transact. Am. Soc. Genit. Uring. Surg., 1977, 68, 29. —
  2. 2. De Bernardi M., Santucci V., Colombo L.\\\\ Pharmacologic treatment of benign prostatic hyperplasia. A multicenter clinical study with Mepartricin. Curr. Ther. Res., 1988, 43, 6, 1159. —
  3. 3. Dreikorn K., Richter K.: Conservative nonhormonal treatment of patients with benign prostatic hyperplasia. New Developments in Biosciences, 1989, 5, 109. —
  4. 4. Dutkiewicz S.: Przydatność leków blokujących receptory al adrenergiczne w zachowawczym leczeniu łagodnego rozrostu stercza. Praca habilitacyjna. Biuletyn WAM, Łódź, 1990. —
  5. 5. Lotti T., Mirone V., Prezioso D., De Bernardi M., Rapocci M. P. Ruozi P.: Obserations on some hormone fractions in patients with benign prostatic hyperplasia treated with Mepartricin. Curr. Ther. Res., 1988, 44, 3, 402. —
  6. 6. Mc Connel J. D.: Medical management of benign prostatic hyperplasia with androgen suppresion. Prostate suppl., 1990, 3, 49. —
  7. 7. Schaffner G. P.: Effect of cholesterol--lowering agents. Hinman F. Jr (ed) Benign prostatic hypertrophy Springer-Verlag, New York, — Heidelberg — Berlin, 1983, 280. —
  8. 8. Siroky M. B., Olson C. A., Krane R. J.: The flow rate nomogramm: I development. J. Urol., 1978, 122, 665. —
  9. 9. Sporer A., Cohen S., Kamat M. H.: Candicidin: Physiologic affect on prostate. Urology, 1975, 6, 298. —
  10. 10. Swyer G. I. M.: The cholesterol content of normal and enlarged prostates. Cancer Res., 1942, 372.
  11. 11. Tunn V. W., Schweikert H. V.: Aromomatase inhibitors in the management of benign prostatic hyperplasia. New Developments in Biosciences, 1989, 5, 139. —
  12. 12. Vermeulen A., Giagulli V. A., Shepper P. D., Bauntinx A., Stoner A.: Hormonal affects of an orally active 4--azasteroid inhibitor of 5-alfa-reductase in humans. Prostate, 1989, 14, 45.

correspondence

dr n. med. Andrzej Prajsner I Katedra i Klinika Urologii Śl. AM 40-703 Katowice, ul. Strzelecka 9